Pielonefrite aguda


Principais artigos

Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-120.Texto completo  Resumo

European Association of Urology. Guidelines on urological infections. 2022 [internet publication].Texto completo

Artigos de referência

1. Bergeron MG. Treatment of pyelonephritis in adults. Med Clin North Am. 1995 May;79(3):619-49. Resumo

2. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005 Mar 1;71(5):933-42. Resumo

3. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997 Sep;11(3):551-81. Resumo

4. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003 Feb;13(2):144-50. Resumo

5. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis. 2007 Aug 1;45(3):273-80. Resumo

6. Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med. 2005 Jan 4;142(1):20-7. Resumo

7. Ki M, Park T, Choi B, et al. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 2004 Nov 15;160(10):985-93.Texto completo  Resumo

8. Neumann I, Moore P. Pyelonephritis (acute) in non-pregnant women. BMJ Clin Evid. 2014 Nov 4;2014.pii: 0807.Texto completo  Resumo

9. Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Microbiol Spectr. 2016 Oct;4(5). Resumo

10. Valera B, Gentil MA, Cabello V, et al. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc. 2006 Oct;38(8):2414-5. Resumo

11. Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci. 2015 Mar 16;11(1):67-77.Texto completo  Resumo

12. Manges AR, Johnson JR, Foxman B, et al. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001 Oct 4;345(14):1007-13. Resumo

13. Johnson JR, Manges AR, O'Bryan TT, et al. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. Resumo

14. Ramchandani M, Manges AR, DebRoy C, et al. Possible animal origin of human-associated, multidrug-resistant, uropathogenic Escherichia coli. Clin Infect Dis. 2005 Jan 15;40(2):251-7. Resumo

15. Nicolle LE, AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005 Nov;16(6):349-60.Texto completo  Resumo

16. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly population. Am J Geriatr Pharmacother. 2011 Oct;9(5):286-309. Resumo

17. Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007 Jul;72(1):19-25. Resumo

18. Johnson JR. Microbial virulence determinants and the pathogenesis of urinary tract infection. Infect Dis Clin North Am. 2003 Jun;17(2):261-78. Resumo

19. Guyer DM, Kao JS, Mobley HL. Genomic analysis of a pathogenicity island in uropathogenic Escherichia coli CFT073: distribution of homologous sequences among isolates from patients with pyelonephritis, cystitis, and catheter-associated bacteriuria and from fecal samples. Infect Immun. 1998 Sep;66(9):4411-7.Texto completo  Resumo

20. Hacker J, Blum-Oehler G, Hochhut B, et al. The molecular basis of infectious diseases: pathogenicity islands and other mobile genetic elements: a review. Acta Microbiol Immunol Hung. 2003;50(4):321-30. Resumo

21. Boyko EJ, Fihn SD, Scholes D, et al. Diabetes and the risk of acute urinary tract infections among postmenopausal women. Diabetes Care. 2002 Oct;25(10):1778-83.Texto completo  Resumo

22. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol. 2001 Dec;98(6):1045-52. Resumo

23. Pabich WL, Fihn SD, Stamm WE, et al. Prevalence and determinants of vaginal flora alterations in postmenopausal women. J Infect Dis. 2003 Oct 1;188(7):1054-8. Resumo

24. Geerlings SE, Meiland R, van Lith EC, et al. Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells; more in diabetic women than in control subjects. Diabetes Care. 2002 Aug;25(8):1405-9.Texto completo  Resumo

25. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994 Aug;19(2):274-8. Resumo

26. Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000 Oct;182(4):1177-82.Texto completo  Resumo

27. Gupta K, Stapleton AE, Hooton TM, et al. Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998 Aug;178(2):446-50. Resumo

28. National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. September 2017 [internet publication].Texto completo

29. Fairley KF, Carson NE, Gutch RC, et al. Site of infection in acute urinary-tract infection in general practice. Lancet. 1971 Sep 18;2(7725):615-8. Resumo

30. Pinson AG, Philbrick JT, Lindbeck GH, et al. Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med. 1997 Mar;15(2):148-51. Resumo

31. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103-120.Texto completo  Resumo

32. Garin EH, Olavarria F, Araya C, et al. Diagnostic significance of clinical and laboratory findings to localize site of urinary infection. Pediatr Nephrol. 2007 Jul;22(7):1002-6. Resumo

33. Masajtis-Zagajewska A, Kurnatowska I, Wajdlich M, et al. Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections. BMC Urol. 2015 Jul 8;15:67.Texto completo  Resumo

34. Xu RY, Liu HW, Liu JL, et al. Procalcitonin and C-reactive protein in urinary tract infection diagnosis. BMC Urol. 2014 May 30;14:45.Texto completo  Resumo

35. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39(2):206-17. Resumo

36. Azab S, Zakaria M, Raafat M, et al. The combination of urinary IL-6 and renal biometry as useful diagnostic tools to differentiate acute pyelonephritis from lower urinary tract infection. Int Braz J Urol. 2016 Jul-Aug;42(4):810-6.Texto completo  Resumo

37. American College of Radiology. ACR Appropriateness Criteria®. Acute pyelonephritis. 2022 [internet publication].Texto completo

38. Stunell H, Buckley O, Feeney J, et al. Imaging of acute pyelonephritis in the adult. Eur Radiol. 2007 Jul;17(7):1820-8. Resumo

39. Garcia-Ferrer L, Primo J, Juan Escudero JU, et al. The use of renal ultrasound for adult acute pyelonephritis. Arch Esp Urol. 2007 Jun;60(5):519-24. Resumo

40. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2019 Nov 25;2019(11):.Texto completo  Resumo

41. US Preventive Services Task Force., Owens DK, Davidson KW, et al. Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Sep 24;322(12):1188-94.Texto completo  Resumo

42. Schneeberger C, Geerlings SE, Middleton P, et al. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev. 2015 Jul 26;(7):CD009279.Texto completo  Resumo

43. Farkash E, Weintraub AY, Sergienko R, et al. Acute antepartum pyelonephritis in pregnancy: a critical analysis of risk factors and outcomes. Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):24-7. Resumo

44. European Association of Urology. Guidelines on urological infections. 2022 [internet publication].Texto completo

45. Bosch-Nicolau P, Falcó V, Viñado B, et al. A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis. Antimicrob Agents Chemother. 2017 Dec;61(12):.Texto completo  Resumo

46. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021 Apr 8;72(7):e169-e83.Texto completo  Resumo

47. Cattrall JWS, Robinson AV, Kirby A. A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 2018 Dec;37(12):2285-2291.Texto completo  Resumo

48. Bergeron MG, Marois Y. Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis. Kidney Int. 1986 Oct;30(4):481-7. Resumo

49. European Medicines Agency: Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Mar 2019 [internet publication].Texto completo

50. Food and Drug Agency (FDA). FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients.Texto completo

51. Food and Drug Agency (FDA). FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Texto completo

52. Piccoli GB, Consiglio V, Colla L, et al. Antibiotic treatment for acute 'uncomplicated' or 'primary' pyelonephritis: a systematic, 'semantic revision'. Int J Antimicrob Agents. 2006 Aug;28(suppl 1):S49-63. Resumo

53. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection - 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013 Oct;68(10):2183-91. Resumo

54. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90. Resumo

55. Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: Best practice advice from the American College of Physicians. Ann Intern Med. 2021 Apr 6;:.Texto completo  Resumo

56. Glaser AP, Schaeffer AJ. Urinary tract infection and bacteriuria in pregnancy. Urol Clin North Am. 2015 Nov;42(4):547-60.Texto completo  Resumo

57. Widmer M, Gülmezoglu AM, Mignini L, et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. 2015 Nov 11;(11):CD000491.Texto completo  Resumo

58. Vouloumanou EK, Rafailidis PI, Kazantzi MS, et al. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials. Cur Med Res Opin. 2008 Dec;24(12):3423-34. Resumo

59. Safrin S, Siegel D, Black D. Pyelonephritis in adult women: inpatient versus outpatient therapy. Am J Med. 1988 Dec;85(6):793-8. Resumo

60. Pinson AG, Philbrick JT, Lindbeck GH, et al. ED management of acute pyelonephritis in women: a cohort study. Am J Emerg Med. 1994 May;12(3):271-8. Resumo

61. Rudrabhatla P, Deepanjali S, Mandal J, et al. Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelonephritis requiring hospitalization: A randomized non-inferiority trial. PLoS One. 2018;13(5):e0197302.Texto completo  Resumo

62. Onakpoya IJ, Walker AS, Tan PS, et al. Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care. PLoS One. 2018;13(3):e0194858.Texto completo  Resumo

63. Hanretty AM, Gallagher JC. Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. Pharmacotherapy. 2018 Jun;38(6):674-687.Texto completo  Resumo

64. Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD002256.Texto completo  Resumo

65. Popović J, Grujić Z, Sabo A. Influence of pregnancy on ceftriaxone, cefazolin and gentamicin pharmacokinetics in caesarean vs. non-pregnant sectioned women. J Clin Pharm Ther. 2007 Dec;32(6):595-602. Resumo

66. Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006 May;107(5):1120-38. Resumo

67. Gupta R, Verma I, Sharma S, et al. Prevention of tissue injury in an ascending mouse model of chronic pyelonephritis--role of free radical scavengers. Comp Immunol Microbiol Infect Dis. 2004 Jul;27(4):225-34. Resumo

68. Kucuk HF, Bigul SM, Kurt N, et al. Effect of a selective cyclooxygenase-2 inhibitor on renal scarring. Eur Surg Res. 2006;38(5):451-7. Resumo

69. O'Brien VP, Hannan TJ, Nielsen HV, et al. Drug and vaccine development for the treatment and prevention of urinary tract infections. Microbiol Spectr. 2016 Feb;4(1).Texto completo  Resumo

70. Kumar V, Ganguly N, Joshi K, et al. Protective efficacy and immunogenicity of escheria coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis. Med Microbiol Immunol. 2005 Aug;194(4):211-7. Resumo

71. Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00567-17. Resumo

72. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018 Feb 27;319(8):788-99.Texto completo  Resumo

73. Cox G, Ejim L, Stogios PJ, et al. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-7. Resumo

74. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019 Feb 21;380(8):729-740.Texto completo  Resumo

75. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018 Dec;18(12):1319-1328.Texto completo  Resumo

76. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626.Texto completo  Resumo

77. Wagenlehner FM, Lichtenstern C, Rolfes C, et al. Diagnosis and management for urosepsis. Int J Urol. 2013 Oct;20(10):963-70.Texto completo  Resumo

78. Bonkat G, Cai T, Veeratterapillay R, et al. Management of Urosepsis in 2018. Eur Urol Focus. 2019 Jan;5(1):5-9.Texto completo  Resumo

79. Wagenlehner FM, Vahlensieck W, Bauer HW, et al. Prevention of recurrent urinary tract infections. Minerva Urol Nefrol. 2013 Mar;65(1):9-20. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal